Earlier this year, the American College of Cardiology, American Heart Association and other organizations published new hypertension guidelines. Learn more about the new guidelines and access hypertension patient education resources on the VHAN Hub Resource Library.
Members of VHAN’s Antibiotic Stewardship team recently developed QuizTime courses to aid in the treatment of pediatric acute respiratory tract infections such as sinusitis and ear infection. Clinicians earn CME credit for each quiz they complete, and the quizzes are free to both Vanderbilt University Medical Center clinicians and non-VUMC clinicians.
As the new year gets underway, we’re reflecting on the most-read VHAN stories of 2025. These articles reflect the work happening across the network, from care coordination and clinical innovation to practical resources that support providers and patients every day.
With the number of patients using weight loss medications on the rise, it can be challenging for providers to identify the best option. Read more to find some key considerations when prescribing GLP-1s.
Statin use is a common and weighty quality measure for many health plans. Understandably, many patients cannot take statins due to intolerance or another condition. However, those cases still count against quality performance unless exclusions are coded annually. The next time you have a patient who cannot use a statin, try one of the codes in our Satin Use Table.
If you’re looking for ways to maximize your patients’ medication coverage, the VHAN Pharmacy Team has tips that can help. Read on for three ways you can increase the likelihood of PA approval for your patients.
Patients who monitor their blood pressure at home typically take a more active role in managing their hypertension and improving their cardiovascular health. But what about patients who need help with the practical details around self-monitoring? Providers can help patients manage their hypertension and obtain appropriate monitoring devices. To help our members and other providers, VHAN has gathered the several strategies and resources to aid in patient education related to hypertension.
VHAN is evolving the network’s clinical services and patient engagement strategies to better meet patients where they are. These services include new diagnosis support programs such as Deviceless Remote Patient Monitoring powered by CareSignal, a company owned by Lightbeam Health Solutions.
Stelara biosimilars Yesintek and Steqeyma have been added to the Navitus formulary effective April 1, 2025. Stelara will be removed from the Navitus formulary effective July 1, 2025. Read the full article for more details on how this change could affect you.